• EMA review cleared use of Greenwich LifeSciences’ commercially manufactured GP2 lot in the Phase III FLAMINGO-01 breast cancer recurrence trial in Europe.
• Move aligns European sites with the US, where FDA review previously allowed the same GP2 vial lot for FLAMINGO-01 use in early 2026.
• Company now pursuing separate regulatory clearances to use the lot in the UK and Canada.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607090600PRIMZONEFULLFEED9759574) on July 09, 2026, and is solely responsible for the information contained therein.